HCV Treatment:  The current treatment for hepatitis C, including outcomes, side effects and treatment of various HCV populations



o   116. HCV-Genotype-Specific Influences on Incident Diabetes: the Effect of Sustained Viral Response to Antiviral Therapy.

o   117. Sustained Virologic Response is Independently Associated with Improvement in Insulin Resistance in Genotype 1, but not Genotype 2/3, Chronic HCV Patients.

o   124. A Novel Innate Immune Mechanism of Action of Ribavirin in Antiviral Therapy.

o   758.  Use of Telemedicine and the “Warm Line” for the Treatment of Hepatitis C Infection (HCV) in the Correctional Setting to Reduce Barriers to Specialty Care. (updated Nov 11, 2009)

o   774. Immediate versus delayed antiviral treatment in patients with acute hepatitis C: A model-based decision analysis. (updated Nov 2, 2009)

o   795. Clinical efficacy and cost effectiveness analysis of peginterferon and ribavirin therapy in patients after curative treatment for hepatocellular carcinoma associated with hepatitis C.

o   802. Long term follow-up of chronic hepatitis C patients after interferon based anti-viral therapy. (updated Nov 11, 2009)

o   812. Retreatment With Peginterferon (PEG-IFN) alfa-2b Plus Ribavirin (RBV) of Chronic Hepatitis C Genotype 1 Patients Who Were Nonresponders to Peginterferon alfa-2a: Final Results of ESPECIAL.

o   815. Retreatment of Chronic Hepatitis C- Genotype 1-infected Relapsers to Peginterferon/ribavirin with Consensus interferon/ribavirin or with Extended Duration Therapy Peginterferon/ribavirin.

o   819. Low-to-moderate alcohol consumption has no impact on antiviral response to combination therapy in HCV patients with genotype 2 or 3. (updated Nov 2, 2009)

o   820. Determinants of virologic relapse following hepatitis C antiviral therapy: Analysis of the Canadian POWeR Program.

o   831. Sustained Virological Responders to Pegylated Interferon and Ribavirin Therapy may Show Transient HCV-RNA Positivity when Adequately Followed Up. Clinical Associations and Significance of this Phenomenon During 7-Year Follow-up of 506 Treated Patients.

o   873. Non-compliance with current guidelines for treatment of chronic hepatitis C (CHC) is frequent in daily practice and may lead to an increase in SVR: Results of a large prospective cohort study.

o   901. Impact of therapeutic education on the outcome of chronic hepatitis C treatment.

o   969. Preliminary Observational Study on Efficacy and Tolerability Of PEG-IFN On 151 Pediatric and Adolescent Chronic Hepatitis C Patients (updated Nov 13, 2009)

o   1554. Treatment of genotype 2 or 3 hepatitis C virus infection with pegylated interferon and weight based ribavirin: A meta-analysis comparing short term [12-16 wks] vs. regular duration [24 wks] treatment.


      HCV Populations

o   African Americans

§  848. Analysis of Reasons for Treatment Ineligibility in the IDEAL study: African Americans (AA) vs non-African Americans (non-AA). (updated Nov 2, 2009)


o   Asians

§  889. Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study.


o   Hemodialysis

§  829. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.


o   Hispanics

§  849. Efficacy of a “on-treatment viral response tailored regimen” with peginterferon (PegIFN) alfa 2b plus ribavirin in naïve genotype 1 chronic hepatitis C (CHC) Mexican patients.


o   HIV/HCV Coinfection

§  843. Extension of Combination Therapy in HCV/HIV Co-infected Genotype 1 Patients: Effect on SVR.


o   IDU

§  805. Treatment of chronic hepatitis C virus infection in IVDU: long term (4 year) follow up. (updated Nov 10, 2009)

§  813. Combination antiviral therapy for chronic hepatitis C in illicit drug users: meta-analysis of prospective studies.

§  887. Determinants of Engagement in Care of Inner City HCV-Infected Injection Drug Users (IDUs). (updated Nov 10, 2009)

§  888. Treatment of recent hepatitis C virus infection in a predominantly injection drug user cohort: the ATAHC Study.

§  891. Viral Hepatitis In IVDUs: A 14-Year Experience Of A Single Liver Unit - Epidemiological And Clinical Data.

§  894. The impact of chemical dependency diagnosis and treatment on treatment of chronic hepatitis C (HCV) in patients in a stable insured population.



o   61. Standard versus higher induction doses of peginterferon alfa-2a (40KD) and/or higher ribavirin (RBV) in HCV G1 patients with high viral load and body weight ≥85 kg: Final results of the PROGRESS study.

o   115. Outcome of Sustained Virological Responders (SVR) and Non-responders in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial

o   1556. Highly Effective Peginterferon Alpha-2a plus Ribavirin Combination Therapy for Chronic Hepatitis C in Patients with Hemophilia.

o   1561. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: Final results of the PARADIGM study.



o   850. Outcomes of a large, inclusive population-based hepatitis C treatment program are similar to randomized controlled trials: Interim results of the Canadian REDIPEN Program. (updated Nov 2, 2009)



o   880. Treatment compliance in patients taking RibaPak® or ribavirin 200mg: Final analyses from the ADHERE registry. (updated Nov 2, 2009)


      Side Effects

o   794. Global review of the rate of interstitial pneumonitis among hepatitis virus C-infected patients treated with pegylated interferon ± ribavirin. (updated Nov 2, 2009)

o   828. Thrombocytopenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C is not associated with severe bleedings.


      Treatment Outcomes

o   119. Long-term Survival of Sustained Virologic Responders to Pegylated Interferon Therapy for Chronic Hepatitis C.